In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

CLICK HERE FOR CME CREDIT

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Stefano Del Prato, MD PhD

Stefano Del Prato, MD PhD

Professor of Endocrinology and Metabolism School of Medicine, University of Pisa Chief of the Section of Diabetes University of Pisa, Italy Clinical Associate Professor of Medicine University of Texas, San Antonio Health Science Center San Antonio, Texas